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Abstract 
Introduction: We glad to introduce several variants of pharmacological correction of 
ischemic hepatic injury by imidazoline I2 receptor agonist С7070. 
Materials and methods: The experiment was carried out on 70 rats of both sexes, divided 
into 7 groups (n = 10): an intact group; Pseudo-operated animals (autopsy of the abdominal 
wall without ligation of the liver vessels); Ischemia / reperfusion group without drug 
correction; Animals undergoing ischemia / liver reperfusion + Metformin (50 mg / kg); 
Animals undergoing ischemia / liver reperfusion + Moxonidine (1 μg / kg); Animals 
undergoing ischemia / liver reperfusion + C7070 (1 mg / kg). For the evaluation, the 
coefficients calculated from the level of hepatic transaminases (ALT, AST), as well as 
morphometric ratios of the area of necrosis and deep ischemia of the liver, were used for 
the evaluation according to the histological examination. 
Results and discussion: The indicated agonists of peripheral imidazoline I2receptors (C7070) 
significantly reducesischemically-reperfusion injury of the liver, in comparison with the 
preparations of moxonidine and metformine. Indirect sign of imidazoline activating 
mechanism of C7070 is decreasing of the hepatoprotective effect of C7070 by the preliminary 
administration of imidazoline receptor blocker BU-224. The coefficients for ALT / AST for 
C7070, moxonidine and metformin were 72.8 / 62.13, respectively; 44.99 / 34.20 and 36.88 / 
21.02. The coefficients of the morphological hepatoprotective activity of the preparations were: 
С7070 – 82.61, moxonidine – 72.33, metformin – 38.96. 
Conclusions: The imidazoline receptor agonists significantly and significantly reduce the 
functional and morphological manifestations of liver ischemia / reperfusion. 
Keywords: Liver ischemia, liver reperfusion, diabetes mellitus, C7070, moxonidine, 
metformin, imidazoline receptor agonists. 
Introduction 
Ischemia may be considered as a trigger 
moment and part of pathway of numerous 
pathological conditions [1]. 
The development of new effective medicines 
for diabetes mellitus treatment is one of the most 
actual problems nowadays. As known, this 
development is enable without studying of 
pharmacokinetic [2]. 
In case of diabetes mellitus and a metabolic 
syndrome the fatty dystrophy develops. It can rise 
to hepatic necrosis [3]. 
Modern drugs of metabolic syndrome and 
diabetes mellitus treatment do not protect liver 
effectively. 
Rus.  
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Remembering this, we are able to assert, that 
studying of additional pharmacological correction 
of standard therapy by biguanides is scientifically 
interests [4]. 
Materials and methods 
The studying of hepatic anti-ischemic activity 
was conducted by D.A. Lopatin method [5]. 
In the experiment were included 50 both sex 
adult rats, divided in 5 groups: intact group, pseudo-
operated group, control group (moderated 
pathology without therapy); and3 groups with 
treatment by C7070 (1 mg/kg), moxonidine  
(1 g/kg) and metformine (50 mg/kg). 
The studying drugs were administrated 
before moderating a pathology. 
The animals were narcotized by 
inroperitoneal administration of chloralhydrate in 
dose 300 mg/kg. 
Narcotized animal was subjected to the 
median laporotomy through the lineaalba. 
Ligamentum hepatica major was stupid stood and 
pinched by atraumatic clamp for 15 minutes. 
Then, content of abdominal cavity was replaced 
back. A surgical wound was sawed in layers. 
During 3 days studying drugs were 
administrated into the animals per os. 
3 days after the end of experiment animals 
were euthanized by diethyl ether with subsequent 
taking blood from the heart. The blood was 
analyzed for ALT, AST. 
There was none death during the experiment. 
ALT and AST were chosen as biochemical 
markers of ischemic injury [6]. 
Histological sections were selected as 
morphological markers of ischemic injury [7]. 
All differences, detected by comparing of 
stated parameters, received in different groups 
were considered as statistically significant in case 
of p<0.05. 
Results and discussion 
Moderating of 15 minute ischemia with 
subsequent reperfusion caused to the increasing 
of ALT and AST level by 3rd day in 5 times  
(tab. 1). Pseudo-operated animals did not 
different from intact group. The same time, 
morphometric metering of ischemic injury area 
and necrosis area was 0.387±0.014 and 
0.207±0.021 respectively (tab. 2). 
Table 1 
The influence of agonists of imidazoline receptors at the level of ALT and AST in modeling  
of ischemia/reperfusion of the liver (M±m, n=10) 
 
Animal group ALT (U/ml) AST (U/ml) 
Intact 102.89±8.82 284.14±19.36 
Pseudo-operated 110.27±21.96* 289.80±16.29* 
Ischemia/Reperfusion (I/R) 526.90±17.97** 1045.16±80.02** 
I/R+С7070 (1 mg/kg) 143.27±16.931 395.85±33.311 
I/R +Moxonidine (1 /kg) 289.86±15.271 687.71±28.371 
I/R +Metformine (50 mg/kg) 332.56±22.051 825.49±22.461 
I/R +С7070 (1 mg/kg)+BU224 (1 mg/kg) 300.45±19.441 798.59±21.341 
Note: * – p>0.05 incomparing with intact group, ** – p>0.05 incomparing with pseudo-operatedgroup, 1 – p>0.05 incomparing 
with ischemia/reperfusion group. 
Table 2 
The influence of agonists of imidazoline receptors in the area of ischemic damage to the liver and area of the 
zone of necrosis of liver tissue by modeling of ischemia/reperfusion of the liver (M±m, n=10) 
 
Animal group Ischemia injury area, mm2 Necrosis area, mm2 
Intact n/a n/a 
Pseudo-operated n/a n/a 
Ischemia/Reperfusion (I/R) 0.387±0.014 0.207±0.021 
I/R+С7070 (1 mg/kg) 0.058±0.029* 0.046±0.013* 
I/R +Moxonidine (1 /kg) 0.090±0.025* 0.075±0.015* 
I/R +Metformine (50 mg/kg) 0.238±0.052* 0.125±0.020* 
I/R +С7070 (1 mg/kg)+BU224 (1 mg/kg) 0.159±0.031* 0.104±0.008* 
Note: * – p>0.05 incomparing with ischemia/reperfusion group. 
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Using of studying drugs statistically 
significant decrease the level of ALT and AST in 
experimental animals. Maximal activity had 
C7070 (1 mg/kg), the level of ALT and AST were 
143.27±16.931 and 395.85±33.311 respectively 
(tab. 1). 
The same time C7070 significantly decreased 
ischemia injury area and necrosis area till 
0.058±0.029 and 0.046±0.013 respectively.  
Metformine and moxonidine decreased 
biochemical and morphometrical markers of 
ischemia injury, but they were worse than C7070 
(tab. 1-2). 
For the ease evaluation we offer to compare 
the degree of AST and ALT level decreasing in 
different animal groups. It is possible with help of 
simple math formula 1. 
К𝐴𝐿𝑇 = 100 −
𝐴𝐿𝑇 (𝑒𝑥𝑝)
𝐴𝐿𝑇 (𝑐𝑡𝑟𝑙)
∗ 100%,                 (1) 
ALT (exp) – ALT level in blood of 
experimental animals,  
ALT (ctrl) – ALT level in blood of control 
(I/R) animals. 
 
The same formula (formula 2) may be 
useful for AST studying. 
К𝐴𝑆𝑇 = 100 −
𝐴𝑆𝑇 (𝑒𝑥𝑝)
𝐴𝑆𝑇 (𝑐𝑡𝑟𝑙)
∗ 100%,            (2) 
AST (exp) – AST level in blood of 
experimental animals,  
AST (ctrl) – AST level in blood of control 
(I/R) animals. 
 
With the help of previous formulas we can 
take next data of functional activity of studing 
drugs (tab.3).  
Table 3 
Hepatoprotective activity С7070, moxonidine and Metformin in modeling of ischemia/reperfusion  
of the liver according biochemical research (M±m; n=10) 
 
Hepatoprotective coefficient, 
U. 
С7070 (1 mg/kg) Moxonidine (1 /kg) Metformine (50 mg/kg) 
КALT 72.81±1.71* 44.99±1.23 36.88±1.02 
КAST 62.13±1.34* 34.20±1.21 21.02±1.49 
Note: * – p>0.05 incomparing with moxonidine and metformine groups. 
 
Based on these data we are able to speak 
about maximal anti-ischemic activity of 
imidazoline I2 agonist (C7070) through the all 
studied in frames of this studying drugs. 
There are not enough data for the full 
assessment of anti-ischemic activity of studying 
drugs. 
The coefficient of morphological 
hapetoprotection was chosen as additional data 
for full assessment of anti-ischemic activity for 
the studying drugs. This coefficient include data 
of ischemic injury area and necrosis area.  
The coefficient was calculated by next 
formula (formula 3). 
К = 100% − (
М𝑖(𝑒𝑥𝑝)+М𝑛(𝑒𝑥𝑝)
М𝑖(𝑐𝑡𝑟𝑙)+М𝑛(𝑐𝑡𝑟𝑙)
∗ 100%),        (3) 
Мi (exp) – mean area of ischemic injury of 
liver in experimental animals; 
Мn (exp) – mean necrosis area in liver of 
experimental animals; 
Мi (ctrl) –mean area of ischemic injury of 
liver in control (I/R) animals; 
Мn (ctrl) – mean necrosis area in liver of 
experimental animals. 
 
Thus we receive next data of morphological 
anti-ischemic activity of studied drugs. (tab. 4) 
 
Table 4 
Hepatoprotective activity С7070, moxonidine  
and Metformin when modelirovanii 
ischemia/reperfusion of the liver according 
moramerica research (M±m; n=10) 
 
Animal group 
Coefficient of 
hepatoprotective 
activity, U.  
И/Р+С7070 (10 мг/кг) 82.61±3.22* 
И/Р+Moxonidine (1 
мг/кг) 
72.33±1.04 
И/Р+Metformine (50 
мг/кг) 
38.96±5.69 
Note: * – р<0.05 in comparing with. 2 и 3. 
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So, agonist of peripheral imidazoline 
receptor (I2) C7070 has maximal anti-ischemic 
activity among all studied drugs.  
Received data are able to be explained by 
different mechanism of action. 
The base of metformine action is a decreasing 
of glucose production. 
Itcorrelatedwiththedecreasingofglycemialevel.M
etformine plays a role in increasing of peripheral 
insulin effects, decreasing gluconeogenesis and 
oxidation of free fat acids in liver, increasing of 
anaerobes way of glucose metabolism with the 
lactate formation, decreasing of lipolisis. In range 
of in vivo and in vitro studies was detected 
activating influence of metformine on the cell 
ferment AMP-kinase, playing a role in glucose 
transport by GLUT4 and oxidation of free fat 
acids. Probably, betterment of glycemic profile by 
metformine therapy may be related to the same 
aspects of its mechanism of action. Besides, 
dimethylbiguanide demonstrated an ability to 
decrease the rigidity of cell membranes, which 
often detected at patient with diabetes and can 
contribute the development of its complications 
[8]. 
Metformine asctivates AMPK – hepatic 
ferment, playing a role in insulin signalization, in 
total energy balance in organism and in glucose 
and lipid metabolism, including liver. Activation 
of AMPK is necessary for inhibition metformine 
effect to hepatic gkuconeogenesis [9]. 
Resuming of previous, it can be argued that 
anti-ischemic action of metformine based on the 
accumulation of hepatocytes energy reserves and 
deceleration of in spending generated current 
nutrients. 
Moxonidine as an agonist of central (I1) 
imidazoline receptor involved in redistribution of 
hepatic blood flow according to opening of 
collateral vessels, started from a. gastricasinistra, 
free from the blocking. Also, additional activity 
can due to the central control by moxonidine on 
the opening of hepatic vessels in moment of 
reperfusion. It can’t be excluded the influence of 
moxonidine to the peripheral imidazoline 
receptors [10]. 
The agonist of peripheral imidazoline (I2) 
receptors C7070 releases its hepatoprotective 
action by mechanisms, like in case of skin flap 
ischemia. Obliviously, its influence to the 
preservation of mitochondria using ATPase 
canals, presented on the external and internal 
mitochondrial membranes. Slowing and blocking 
of avalanche ferric ion current decrease the 
oxidative stress with all its manifestations during 
the reperfusion of liver [11]. 
Activation of the imidazoline receptors 
results to the rise of arachnid acid synthesis and 
inhibition of Na+/H+ ion exchange canals. It 
seems, that imidazoline receptors belong to the 
neurocytokine receptors [12]. Activation of the 
central imidazoline (I1) receptors leads to the 
decreasing of the blood pressure and slows a 
heartbeat. These all are the result of braking 
influence to the peripheral sympatic nervous 
system. 
During the time we know the new generation 
of the imidazoline receptors agotists there were 
many pre-clinical and clinical trials of 
effectiveness of these drugs. 
So, Mukaddam-Daher in his trial shows, that 
intravenous administration of moxonidinerised 
rat diuresis and Na/K excretion. This effect was 
blocked by administration of 
imidazolinereseptors antagonist epharoxan and 
decreased by effect of α-andrenoblocker – 
jobichinin [13]. 
Central imidazoline (I1) receptors of 
hypothalamic area are involved into the glycemic 
level regulation, that was shown at the experiment 
with the selective I1 receptor agonist agmantine, 
which causes the decreasing of glucose level in 
blood. The same action has moxonidine. Besides, 
it is assumed, that imidazoline receptors can be 
located in pancreas. Activation of these receptors 
is able to leads to increasing insulin secretion 
[14]. 
Using of moxonidine at Zucker line rats 
caused decreasing the level of hypothalamic 
neuropeptid Y, that may be one of the probably 
mechanism explaining the decrease in body mass 
during therapy with this drug [15]. 
It should be noted that not all of these effects 
can be explained by the activation of central 
I1−receptors. Apparently, some of them still 
mediated by α2−adrenergic receptors. In addition, 
a certain contribution is made by the peripheral 
action of drugs. 
Representatives of the Kharkov 
pharmaceutical schools, by contrast, drew 
attention to the ability of agonists of peripheral 
imidazoline receptors influence glycemic control 
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[16]. According to their research, this group of 
drugs in its hypoglycemic action is not inferior to 
Metformin. But the unwanted side effects they 
have much less. Moreover, unlike Metformin, 
agonists peripheral imidazoline receptors do not 
cause the development of hypoproteinemia and 
hyperlactacidemia. 
In addition to its other localizations, 
imidazoline receptors located on the membranes 
of adipocytes — fat cells. Stimulation of these 
receptors leads to increased lipid metabolism. 
In the treatment of moxonidine (0.4 mg/day) 
for 8 weeks in 20 patients with hypertension there 
was a significant decrease in blood pressure, but 
the levels of total lipids, oxidized low-density 
lipoprotein and the ratio of different subtypes of 
lipoproteidov low density did not change 
significantly [17]. In an 8−week study, involving 
51 patients with hypertension and 
hypercholesterolemia did not affect the level of 
blood lipids and rilmenidine [18]. 
The history of biguanide derived from 
guanidine – thing of the past. In the Middle ages 
for the treatment of patients with diabetes used an 
extract from the root of the French lilac. The drug 
Galegaofficinalis contained a substance 
"guanidine" which was aimed at reducing the 
clinical symptoms of diabetes. 
Since, at this time established a significant 
correlation of insulin resistance with the activity 
of the sympathetic nervous system, it is logical 
that you need a "universal" tool that would control 
and glycemia, and insulin resistance and SNS 
activity. 
Besides, do not forget that the role of 
endothelial cells in the development of 
cardiovascular disease was an important 
discovery for understanding pathogenesis 
including diabetic vascular lesions [19]. 
Modern hypoglycemic medicines may have 
positive pleiotropic effects on the pancreatic 
tissue. However, their activity is insufficient to 
prevent the development spotswoode diabetes 
complications [20]. 
In view of the foregoing, it becomes apparent 
the advantage of agonists of peripheral 
imidazoline receptors (IR2) as drugs that affect 
the early survival of patients with diabetes 
mellitus type II. 
Conclusion 
1.Theimidazoline I2 receptors agonist С7070 
at a dose of 1 mg/kg at 4.5 times prevents the 
increase of ALT and AST and at 2.5 times reduces 
areaof ischemic injury and necrosis in the 
modereating of a 15-minute ischemia of the 
liver.Hepatoprotective effect of С7070 50% 
decreased by antagonist of peripheral 
imidazolinereceptors BU224 (1 mg/kg) 
2. Moxonidin andmetformine also has a 
hepatoprotective effect and their coefficients are 
36.88% to 44.99% for moxonidine (ALT and 
AST) and 34.20/21.02 for Metformin 
(ALT/AST). Factors histological 
hepatoprotective activity amounted to 72.33 and 
38.96 for moxonidine and metformine 
respectively. 
3. On hepatoprotective activity of the drug 
was inferior С7070 (72.81/62.13/82.61 
ALT/AST/histology, respectively). 
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